{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T19:39:36Z","timestamp":1792697976054,"version":"4.5.0"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,12,7]],"date-time":"2020-12-07T00:00:00Z","timestamp":1607299200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,12,7]],"date-time":"2020-12-07T00:00:00Z","timestamp":1607299200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100008903","name":"Ministry of Health and Welfare","doi-asserted-by":"publisher","award":["107-TDU-B-211-123002, 108-TDU-B-211-133002"],"award-info":[{"award-number":["107-TDU-B-211-123002, 108-TDU-B-211-133002"]}],"id":[{"id":"10.13039\/100008903","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>A significantly negative reversion in the QuantiFERON-TB Gold In-tube (QFT-GIT) test is reported in patients on dialysis, which makes the results unreliable. The CD4 and CD8 responses of the QFT-Gold plus (QFT-Plus) may have better positive consistency, but this needs to be investigated. We enrolled dialysis patients with baseline positive QFT-GIT<jats:sub>0<\/jats:sub> results and conducted two rounds of follow-up paired QFT-GIT<jats:sub>1&amp;2<\/jats:sub> and QFT-Plus<jats:sub>1&amp;2<\/jats:sub> tests at an interval of 6\u00a0months. The positive consistency, concordance, and discordance of the QFT results were analyzed. A total of 236 patients on dialysis were screened, and 73 participants with positive QFT-GIT<jats:sub>0<\/jats:sub> results were enrolled. The baseline QFT-GIT<jats:sub>0<\/jats:sub> response was higher in the 1st QFT-Plus<jats:sub>1<\/jats:sub>(+) group than in the QFT-Plus<jats:sub>1<\/jats:sub>(\u2212) group, but insignificantly different between the 1st QFT-GIT<jats:sub>1<\/jats:sub>(+) and QFT-GIT<jats:sub>1<\/jats:sub>(\u2212) groups. The two assays had good correlation when concurrently tested. Fifty-three subjects completed a second round of the QFT-GIT<jats:sub>2<\/jats:sub> and QFT-Plus<jats:sub>2<\/jats:sub>. Persistent positivity was higher with the QFT-Plus<jats:sub>2<\/jats:sub> (81.8%) than with the QFT-GIT<jats:sub>2<\/jats:sub> (58.8%, p\u2009=\u20090.040). The QFT-GIT<jats:sub>1<\/jats:sub> and QFT-Plus<jats:sub>1<\/jats:sub> CD4 responses were higher in patients with persistent positivity than in those with negative reversion, whereas the difference of the QFT-Plus TB1 and TB2 data, representative of the CD8 response, were similar between positive persistence and negative reversion. In conclusion, the QFT-Plus provides more reliable positive consistency than does the QFT-GIT. The CD4 interferon-\u03b3 response might play a role in maintaining positivity of LTBI.<\/jats:p>","DOI":"10.1038\/s41598-020-78374-3","type":"journal-article","created":{"date-parts":[[2020,12,7]],"date-time":"2020-12-07T11:07:06Z","timestamp":1607339226000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["CD4 response of QuantiFERON-TB Gold Plus for positive consistency of latent tuberculosis infection in patients on dialysis"],"prefix":"10.1038","volume":"10","author":[{"given":"Ping-Huai","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shu-Yung","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan Shih-Jung","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shu-Wen","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chih-Yuan","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-Feng","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chin-Chung","family":"Shu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jann-Yuan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chong-Jen","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,12,7]]},"reference":[{"key":"78374_CR1","unstructured":"World Health Organization, Geneva, Switzerland, 2019."},{"key":"78374_CR2","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.00655-2019","author":"A Cohen","year":"2019","unstructured":"Cohen, A., Mathiasen, V. D., Schon, T. & Wejse, C. The global prevalence of latent tuberculosis: a systematic review and meta-analysis. Eur. Respir. J. https:\/\/doi.org\/10.1183\/13993003.00655-2019 (2019).","journal-title":"Eur. Respir. J."},{"key":"78374_CR3","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1186\/1471-2334-14-387","volume":"14","author":"J Liu","year":"2014","unstructured":"Liu, J., Yan, J., Wan, Q., Ye, Q. & Huang, Y. The risk factors for tuberculosis in liver or kidney transplant recipients. BMC Infect. Dis. 14, 387. https:\/\/doi.org\/10.1186\/1471-2334-14-387 (2014).","journal-title":"BMC Infect. Dis."},{"key":"78374_CR4","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1159\/000045974","volume":"88","author":"KJ Chou","year":"2001","unstructured":"Chou, K. J. et al. Tuberculosis in maintenance dialysis patients. Nephron 88, 138\u2013143. https:\/\/doi.org\/10.1159\/000045974 (2001).","journal-title":"Nephron"},{"key":"78374_CR5","doi-asserted-by":"publisher","first-page":"1563","DOI":"10.1183\/13993003.01245-2015","volume":"46","author":"H Getahun","year":"2015","unstructured":"Getahun, H. et al. Management of latent Mycobacterium tuberculosis infection: WHO guidelines for low tuberculosis burden countries. Eur. Respir. J. 46, 1563\u20131576. https:\/\/doi.org\/10.1183\/13993003.01245-2015 (2015).","journal-title":"Eur. Respir. J."},{"key":"78374_CR6","doi-asserted-by":"publisher","first-page":"928","DOI":"10.1183\/09031936.00214014","volume":"45","author":"K Lonnroth","year":"2015","unstructured":"Lonnroth, K. et al. Towards tuberculosis elimination: an action framework for low-incidence countries. Eur. Respir. J. 45, 928\u2013952. https:\/\/doi.org\/10.1183\/09031936.00214014 (2015).","journal-title":"Eur. Respir. J."},{"key":"78374_CR7","first-page":"46","volume-title":"Toman\u2019s tuberculosis Case detection, treatment and monitoring","author":"A Harries","year":"2004","unstructured":"Harries, A. In Toman\u2019s tuberculosis Case detection, treatment and monitoring (ed. Frieden, T. R.) 46\u201350 (World Health Organization, Geneva, 2004)."},{"key":"78374_CR8","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1378\/chest.113.1.25","volume":"113","author":"M Smirnoff","year":"1998","unstructured":"Smirnoff, M., Patt, C., Seckler, B. & Adler, J. J. Tuberculin and anergy skin testing of patients receiving long-term hemodialysis. Chest 113, 25\u201327 (1998).","journal-title":"Chest"},{"key":"78374_CR9","doi-asserted-by":"publisher","first-page":"217","DOI":"10.5414\/CNP67217","volume":"67","author":"RK Venkata","year":"2007","unstructured":"Venkata, R. K., Kumar, S., Krishna, R. P., Kumar, S. B. & Padmanabhan, S. Tuberculosis in chronic kidney disease. Clin. Nephrol. 67, 217\u2013220 (2007).","journal-title":"Clin. Nephrol."},{"key":"78374_CR10","first-page":"92","volume":"8","author":"HC Fang","year":"2004","unstructured":"Fang, H. C. et al. Tuberculosis in patients with end-stage renal disease. Int. J. Tuberc. Lung. Dis. 8, 92\u201397 (2004).","journal-title":"Int. J. Tuberc. Lung. Dis."},{"key":"78374_CR11","doi-asserted-by":"publisher","first-page":"1168","DOI":"10.1164\/rccm.201405-0967OC","volume":"190","author":"M Sester","year":"2014","unstructured":"Sester, M. et al. Risk assessment of tuberculosis in immunocompromised patients. A TBNET study. Am. J. Respir. Crit. Care Med. 190, 1168\u20131176. https:\/\/doi.org\/10.1164\/rccm.201405-0967OC (2014).","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"78374_CR12","doi-asserted-by":"publisher","first-page":"e42592","DOI":"10.1371\/journal.pone.0042592","volume":"7","author":"CC Shu","year":"2012","unstructured":"Shu, C. C. et al. Predictors and prevalence of latent tuberculosis infection in patients receiving long-term hemodialysis and peritoneal dialysis. PLoS ONE 7, e42592. https:\/\/doi.org\/10.1371\/journal.pone.0042592 (2012).","journal-title":"PLoS ONE"},{"key":"78374_CR13","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1016\/j.jinf.2013.07.029","volume":"67","author":"CC Shu","year":"2013","unstructured":"Shu, C. C. et al. Dynamic changes in positive interferon-gamma release assay in a dialysis population: an observational cohort study. J. Infect. 67, 529\u2013535. https:\/\/doi.org\/10.1016\/j.jinf.2013.07.029 (2013).","journal-title":"J. Infect."},{"key":"78374_CR14","doi-asserted-by":"publisher","first-page":"e3813","DOI":"10.1097\/md.0000000000003813","volume":"95","author":"CC Shu","year":"2016","unstructured":"Shu, C. C. et al. Risk of tuberculosis among patients on dialysis: the predictive value of serial interferon-gamma release assay. Medicine (Baltimore) 95, e3813. https:\/\/doi.org\/10.1097\/md.0000000000003813 (2016).","journal-title":"Medicine (Baltimore)"},{"key":"78374_CR15","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1164\/rccm.201208-1352OC","volume":"187","author":"IM Adetifa","year":"2013","unstructured":"Adetifa, I. M. et al. Interferon-gamma ELISPOT as a biomarker of treatment efficacy in latent tuberculosis infection: a clinical trial. Am. J. Respir. Crit. Care Med. 187, 439\u2013445. https:\/\/doi.org\/10.1164\/rccm.201208-1352OC (2013).","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"78374_CR16","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1186\/1471-2334-10-220","volume":"10","author":"FC Ringshausen","year":"2010","unstructured":"Ringshausen, F. C. et al. Predictors of persistently positive Mycobacterium-tuberculosis-specific interferon-gamma responses in the serial testing of health care workers. BMC Infect. Dis. 10, 220. https:\/\/doi.org\/10.1186\/1471-2334-10-220 (2010).","journal-title":"BMC Infect. Dis."},{"key":"78374_CR17","doi-asserted-by":"publisher","first-page":"1411","DOI":"10.1183\/13993003.00510-2016","volume":"48","author":"L Barcellini","year":"2016","unstructured":"Barcellini, L. et al. First evaluation of QuantiFERON-TB Gold Plus performance in contact screening. Eur. Respir. J. 48, 1411\u20131419. https:\/\/doi.org\/10.1183\/13993003.00510-2016 (2016).","journal-title":"Eur. Respir. J."},{"key":"78374_CR18","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.00427-18","author":"JY Chien","year":"2018","unstructured":"Chien, J. Y. et al. QuantiFERON-TB Gold Plus is a more sensitive screening tool than QuantiFERON-TB gold in-tube for latent tuberculosis infection among older adults in long-term care facilities. J. Clin. Microbiol. https:\/\/doi.org\/10.1128\/JCM.00427-18 (2018).","journal-title":"J. Clin. Microbiol."},{"key":"78374_CR19","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1016\/j.jinf.2019.01.007","volume":"78","author":"MR Lee","year":"2019","unstructured":"Lee, M. R. et al. CD8 response measured by QuantiFERON-TB Gold Plus and tuberculosis disease status. J. Infect. 78, 299\u2013304. https:\/\/doi.org\/10.1016\/j.jinf.2019.01.007 (2019).","journal-title":"J. Infect."},{"key":"78374_CR20","doi-asserted-by":"publisher","first-page":"30617","DOI":"10.1038\/srep30617","volume":"6","author":"L Yi","year":"2016","unstructured":"Yi, L. et al. Evaluation of QuantiFERON-TB Gold Plus for detection of Mycobacterium tuberculosis infection in Japan. Sci. Rep. 6, 30617. https:\/\/doi.org\/10.1038\/srep30617 (2016).","journal-title":"Sci. Rep."},{"key":"78374_CR21","doi-asserted-by":"publisher","first-page":"2060","DOI":"10.1056\/NEJMsa031667","volume":"350","author":"CR Horsburgh Jr","year":"2004","unstructured":"Horsburgh, C. R. Jr. Priorities for the treatment of latent tuberculosis infection in the United States. N. Engl. J. Med. 350, 2060\u20132067. https:\/\/doi.org\/10.1056\/NEJMsa031667 (2004).","journal-title":"N. Engl. J. Med."},{"key":"78374_CR22","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1093\/aje\/152.3.247","volume":"152","author":"E Vynnycky","year":"2000","unstructured":"Vynnycky, E. & Fine, P. E. Lifetime risks, incubation period, and serial interval of tuberculosis. Am. J. Epidemiol. 152, 247\u2013263. https:\/\/doi.org\/10.1093\/aje\/152.3.247 (2000).","journal-title":"Am. J. Epidemiol."},{"key":"78374_CR23","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1164\/rccm.201203-0430OC","volume":"187","author":"JZ Metcalfe","year":"2013","unstructured":"Metcalfe, J. Z. et al. Test variability of the QuantiFERON-TB gold in-tube assay in clinical practice. Am. J. Respir. Crit. Care Med. 187, 206\u2013211. https:\/\/doi.org\/10.1164\/rccm.201203-0430OC (2013).","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"78374_CR24","doi-asserted-by":"publisher","first-page":"180","DOI":"10.3389\/fimmu.2014.00180","volume":"5","author":"T Prezzemolo","year":"2014","unstructured":"Prezzemolo, T. et al. Functional signatures of human CD4 and CD8 T cell responses to Mycobacterium tuberculosis. Front. Immunol. 5, 180. https:\/\/doi.org\/10.3389\/fimmu.2014.00180 (2014).","journal-title":"Front. Immunol."},{"key":"78374_CR25","doi-asserted-by":"publisher","first-page":"383","DOI":"10.3904\/kjim.2019.002","volume":"35","author":"SH Kim","year":"2020","unstructured":"Kim, S. H., Jo, K. W. & Shim, T. S. QuantiFERON-TB Gold PLUS versus QuantiFERON- TB Gold In-Tube test for diagnosing tuberculosis infection. Korean J. Intern. Med. 35, 383\u2013391. https:\/\/doi.org\/10.3904\/kjim.2019.002 (2020).","journal-title":"Korean J. Intern. Med."},{"key":"78374_CR26","doi-asserted-by":"publisher","first-page":"34577","DOI":"10.1038\/srep34577","volume":"6","author":"CC Shu","year":"2016","unstructured":"Shu, C. C. et al. Inflammatory markers and clinical characteristics for predicting persistent positivity of interferon gamma release assay in dialysis population. Sci. Rep. 6, 34577. https:\/\/doi.org\/10.1038\/srep34577 (2016).","journal-title":"Sci. Rep."},{"key":"78374_CR27","doi-asserted-by":"publisher","first-page":"1568","DOI":"10.1002\/eji.201243262","volume":"43","author":"V Rozot","year":"2013","unstructured":"Rozot, V. et al. Mycobacterium tuberculosis-specific CD8+T cells are functionally and phenotypically different between latent infection and active disease. Eur. J. Immunol. 43, 1568\u20131577. https:\/\/doi.org\/10.1002\/eji.201243262 (2013).","journal-title":"Eur. J. Immunol."},{"key":"78374_CR28","doi-asserted-by":"publisher","first-page":"2222","DOI":"10.4049\/jimmunol.1101122","volume":"187","author":"CL Day","year":"2011","unstructured":"Day, C. L. et al. Functional capacity of Mycobacterium tuberculosis-specific T cell responses in humans is associated with mycobacterial load. J. Immunol. 187, 2222\u20132232. https:\/\/doi.org\/10.4049\/jimmunol.1101122 (2011).","journal-title":"J. Immunol."},{"key":"78374_CR29","doi-asserted-by":"publisher","first-page":"1587","DOI":"10.1183\/13993003.02033-2015","volume":"47","author":"L Barcellini","year":"2016","unstructured":"Barcellini, L. et al. First evaluation of QuantiFERON-TB Gold Plus performance in contact screening. Eur. Respir. J. 47, 1587\u20131590 (2016).","journal-title":"Eur. Respir. J."},{"key":"78374_CR30","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1016\/j.diagmicrobio.2012.11.023","volume":"75","author":"M Nikolova","year":"2013","unstructured":"Nikolova, M. et al. Antigen-specific CD4- and CD8-positive signatures in different phases of Mycobacterium tuberculosis infection. Diagn. Microbiol. Infect. Dis. 75, 277\u2013281. https:\/\/doi.org\/10.1016\/j.diagmicrobio.2012.11.023 (2013).","journal-title":"Diagn. Microbiol. Infect. Dis."},{"key":"78374_CR31","doi-asserted-by":"publisher","first-page":"824","DOI":"10.1164\/ajrccm.163.4.2009100","volume":"163","author":"A Lalvani","year":"2001","unstructured":"Lalvani, A. et al. Rapid detection of Mycobacterium tuberculosis infection by enumeration of antigen-specific T cells. Am. J. Respir. Crit. Care Med. 163, 824\u2013828. https:\/\/doi.org\/10.1164\/ajrccm.163.4.2009100 (2001).","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"78374_CR32","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1186\/1471-2334-10-57","volume":"10","author":"AM Dyrhol-Riise","year":"2010","unstructured":"Dyrhol-Riise, A. M. et al. Diagnosis and follow-up of treatment of latent tuberculosis; the utility of the QuantiFERON-TB Gold In-tube assay in outpatients from a tuberculosis low-endemic country. BMC Infect. Dis. 10, 57. https:\/\/doi.org\/10.1186\/1471-2334-10-57 (2010).","journal-title":"BMC Infect. Dis."},{"key":"78374_CR33","doi-asserted-by":"publisher","first-page":"1623","DOI":"10.5588\/ijtld.11.0017","volume":"15","author":"DB Banach","year":"2011","unstructured":"Banach, D. B. & Harris, T. G. Indeterminate QuantiFERON(R)-TB Gold results in a public health clinic setting. Int. J. Tuberc. Lung Dis. 15, 1623\u20131630. https:\/\/doi.org\/10.5588\/ijtld.11.0017 (2011).","journal-title":"Int. J. Tuberc. Lung Dis."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-78374-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-78374-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-78374-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,7]],"date-time":"2022-12-07T00:42:08Z","timestamp":1670373728000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-78374-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12,7]]},"references-count":33,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2020,12]]}},"alternative-id":["78374"],"URL":"https:\/\/doi.org\/10.1038\/s41598-020-78374-3","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,12,7]]},"assertion":[{"value":"13 July 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 November 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 December 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"21367"}}